Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone.
Haisco Pharmaceutical Group has been on a deal hot streak this year, inking major deals with Eli Lilly, AbbVie and more. The ...
While Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset ...
Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily ...
While Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate ...
The FDA has granted a three-month extension for Capricor Therapeutics’ Duchenne muscular dystrophy hopeful deramiocel in ...
The FDA has placed a clinical hold on RGX-121 after small nodules or cystic masses were detected in the spines of five ...
The current classifications of vaccine recommendations could imply that not all shots require the consent of patients or ...
Not much is known about Boehringer Ingelheim’s drug candidate, dubbed BI 3031185, though the asset has completed at least two ...
Following a tumultuous stretch under ex-Commissioner Marty Makary, current FDA leadership is working to restore reliability, ...
Kaos Capital in a letter to other Capricor Therapeutics shareholders called for “an immediate meeting, board change, and ...
Three fatalities occurring recently in China clinical trials have spurred two members of U.S. Congress to urge the FDA to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results